Amoneta Diagnostics

Luxembourg Institute of Health

Firalis Sas

The University Hospital of Lausanne

The Cardinal Stefa Wuszynski Institute of Cardiology

Firalis Sa

Amoneta Diagnostics Sas

Hueseyin Firat

Eric Schordan

Saliha Moussaoui

Lu Zhang

Samir Ounzain

Thierry Pedrazzini

Yvan Devaux

Martin M Schumacher

Przemyslaw Leszek

Julie Boisclair

Sabrina Danilin

Olivier Grenet

Elias Perentes

The present invention describes a method for the therapeutic treatment and/or for the diagnosis of a brain disorder including but not limited to cognitive disorders such as mild cognitive impairment, Alzheimer disease, frontotemporal dementia, dementia with Lowy body in a subject at risk of having or developing a brain disorder such as cognitive disorder, using long non-coding RNA (lncRNA).

Long non-coding RNAS (LNCRNAS) for the diagnosis and therapeutics of brain disorders, in particular cognitive disorders

The present invention describes a method for the diagnosis of a cognitive disorder including but not limited to Alzheimer disease in a subject at risk of having or developing a cognitive disorder.

Non-coding RNAS (NCRNA) for the diagnosis of cognitive disorders

The present invention provides methods for the diagnosing, monitoring and prognostication of primary and secondary cardiac disorders in a subject based on lncRNA expression. The invention also provides methods for predicting heart failure after myocardial infarction, and differenciation of Ischemic versus non-ischemic Heart Failure. The assessment/quantification of these lncRNAs may also be used as a marker for monitoring drug-induced cardiac toxicities and for the assessment of cardiac involvement during systemic diseases and others disorders/toxicities impacting cardiac function. These lncRNAs are cardiac tissue enriched and may be involved in different cardiac pathophysiological events and represent a potential target for therapeutical approaches.

Diagnostic, prognostic and therapeutic uses of long noncoding RNAs for pathologies and toxicities inducing heart disorders

The present invention is directed to methods for detecting the presence of minimal or early vasculitis or other vasculopathies induced by a cox-2 inhibitor in a subject to whom a cox-2 inhibitor has been administered, selection of cox-2 inhibitory compounds, use of a cox-2 inhibitory compounds in the manufacture of anti-inflammatory medicaments, and vaccination strategies.

Biomarkers for cardiovascular side-effects induced by cox-2 inhibitory compounds

Growing community of inventors

Huningue, France

Hueseyin Firat